Member Info for Amica1

I've looked at several sites in the US for news, virtually nothing, they are still over the counter shares - virtually no credibility, I thought they were intending to list there.

Dave40 should have waited till next week, get many more for his 2k I would bet going by the past month.

There is no market interest in this now it seems, even share chat here & ADVFN way down, let alone the miserable SP, one of the best days for all markets worldwide and this down over 3% at present.

I don't understand why as it seems a sure thing profit wise and has had good press and RNS's - US Gov and BUPA both signed up. I would like to buy more but I want winners, I'm still in loss territory as I bought on the big news day, I'll hold and hope for a while....

Until some institutions start buying in, the 40 to 30 SP is here to stay looks like, so with all this good news I wonder why there is no interest being shown by big money. Maybe big pharma will make an offer?

I don't get it, so what's the guesses on OBD, any comments welcome.

Well it rhymes! Please leave me out of a slanging match, but I think another RNS is due simply because of all the publicity and investor interest, yes it's only a few days after the 'blockbusters' but there are so many questions investors have right now and the momentum is slipping away to an extent. On Int. Investor, for 3 or 4 days OBD was in the top 10 stocks traded, but not now The silly movements in SP are just irritating to most and just re-affirm how dodgy AIM is.

Mainly I'd like to know what they are doing about the US listing on the main markets, the present OTC/pink slip at present does them no favours, and it's the US that's their biggest potential right now.

AIM renowned for being rubbish mostly and the best place to lose money, I know there are some exceptions and small fry have to start here.

Patience is a virtue but it's an old fashioned concept in this frenzied world - especially here!

I'd like to invest more but although I think it's got great potential, AIM and Pink slip just don't have the necessary credibility, even I think I'm being illogical but it's Once bitten, Twice shy...

Thank you 404x for correcting me about press coverage and for listing the publications which I read with renewed optimism for OBD. I wasn’t trolling btw, simply wrong and stupid for not doing sufficient research, so my apologies to you and all for that. I don’t intend intentionally to ramp or de-ramp at any time. I rarely post anything on any forum but do read them on a share I’m interested in and ask questions I have in the hope of answers to speed up research for which I don’t have the time/knowledge to do. I don’t actually have an axe to grind, it would just be nice to have an investment to have confidence in during this bonkers time in the markets and all else in this world.

I’m not bothered by the Director selling, inho, he is just getting a bit of the fruit of his labour, and knowing (I guess) that he will reap a lot more in time to come.

From the articles published it looks as though we have a wait for regulators – NICE etc. in the UK, but faster in the US. I hope that OBD will list soon on the US main market rather than pink slip/over the counter as at present. Don’t know how long that takes. Lot’s of possible scenario’s still until further hard news from OBD as to future intentions, takeovers etc. It must be a very frantic time for OBD with many options as to future strategy.

It would seem that much more testing needs to take place which will take time to do and evaluate to satisfy various healthcare bodies. I have no idea how long it would take before the PSE test would become as prevalent as the PSA is now.

I’m curious to know if Physiomics have been involved in OBD’s research, it might help their SP…

As for MM’s and their manipulation (as always), I guess we have to just live with the fact that it’s going to be very volatile for a while, and the SP isn’t going to make much sense until further news gives more clarity.

GLA

It's a money mag. It ain't the Daily mail.

Thanks to posters who answered some of my questions on OBD. I read an interesting post on ADVFN - the person questioned why Seneca were off-loading shares in OBD and saying that they may know more than the public know which may be the case, it may be down to Co. rules but I doubt it, why would Seneca throw away profits?

Also I'm still puzzled why mainstream media still not reporting, and as far as I know there's not been coverage in prestigious medical journals - New England Journal of Medicine, Lancet, Annals of Internal Medicine, British Medical Journal, and Journal of the American Medical Association.

I know MM's have been manipulating the share price and still will.

My gut feeling is that if this is so good, there wouldn't be so many questions un-answered.

So I'll hold what I have but not add until the murkiness clears, if it's as good as been mooted the price will soon be in pounds. We are a long way from that.

But good luck to all.

Dibs 61 had an intelligent post saying Seneca might have had to sell because of their trading rules which I accept may be the reason they reduced their holding. But if this is so good and obviously a global winner, why the hell are institutions not buying in big time.

Could it be the Co. is in talks about a takeover by big pharma?

I have questions as to what facilities the Co. has to produce everything required to test en-masse in the US and UK and when are the mass market tests due to start, who will review the results etc. etc.

A roll out in the US and UK is going to cost a shed load, where's the cash?

A detailed RNS about the imminent future plans and how funded is really over due now.

And I still don't get why this is still not mass media news

I'm holding my shares - losing money right now and thinking well this is an AIM share, how many times have I seen the dead certainty just be dead.

No more news gives everyone the jitters...

GLA from nervous nellie :-)

I guess SOLI have an arrangement with ii to send the info to shareholders.

Very long winded but well put together and all looked positive

When the markets get out of their morbidity trough, which they will, SOLI SP should do well imho

It's the general despondency that holds the SP back - unfortunately - again imho

Guess we have to wait for next 1 year results (and forget Argentina for a year at least), maybe good then

...................and maybe not, never known this BB and Adfvn to be so negative.

"Pink sheets" is an outdated term used to describe stocks that trade over-the-counter (OTC) rather than on a major U.S. stock exchange. These companies cannot or do not want to meet the requirements for listing on a major U.S. stock exchange like the New York Stock Exchange (NYSE).

People also ask

Is it safe to buy pink sheet stocks?

Many of these stocks tend to be of very small and financially questionable companies, feature wide bid-ask spreads with low liquidity, and are less regulated than large exchanges. Investors should exercise caution and follow their own due diligence before jumping in to trading the OTC markets.

It's OXBOF: but it's a pink sheet share so you can't easily see how it's trading, last price on Bloomberg is $0.14 cents dated Sept. 27th.

Someone said shares were rocketing in the US this morning.

From Simply Wall Street, the following

Risk Checks

We perform automated risk checks on every company. We flag any failed checks as potential investment risks. A company which passes all our checks, however, is not 'risk free'.

Oxford BioDynamics (OXBO.F) Risk Checks

Fail

Are they in a good financial position?

Has less than 1 year of cash runway

Section 4.4

Fail

Is their share price liquid and stable?

Shares are highly illiquid

Share Price

Fail

Have shareholders been diluted over the past year?

Shareholders have been substantially diluted in the past year

Section 7.3

Fail

Are revenue and earnings forecast to grow?

Earnings have declined by 28.8% per year over past 5 years

Section 3.1

Fail

Do they have meaningful levels of revenue?

Makes less than USD$1m in revenue (£289K)

Section 3.1

Fail

Do they have a meaningful market capitalization?

Does not have a meaningful market cap ($75M)

Section 8.0

Pass

Are there any concerning recent events?

No concerning events detected

Share Price

Pass

Do they have sufficient financial data available?

At least 3 years of financial data is available

Section 3.0

Pass

Do they have negative shareholders equity?

OXBO.F does not have negative shareholders equity.

Section 4.2

Pass

Is their dividend sustainable?

They do not pay a dividend

Section 5.0

No data

Are they forecast to achieve profitability?

Insufficient data

Section 2.0

No data

Do they have high quality earnings?

Unprofitable so not applicable

Section 3.1

No data

Have profit margins improved over the past year?

Insufficient data or unprofitable

Section 3.1

No data

Has there been substantial insider selling in the past 3 months?

No 3 month insider trading information

Section 7.1

Not very encouraging.

I'm not de-ramping, I simply want more info before investing big (for me) and I am far from doing that as too many things don't make sense - a typical AIM share it looks like so far.

Could someone post the Times article (it's behind a paywall).

Maybe someone could advise me on how I see current share info in the US (I don't know what a pink sheet share is except that it's illiquid. I will try and find out myself.

Thanks in advance

The Times article is Business news. It's not really mainstream either - Daily Mirror/Express/Daily Mail etc. are. And Radio/TV of course. My point is that the SP would rocket IF it was mainstream news, it's not right now, the news is priced in.

£750 for a test is very pricey in these hard times, that will deter a lot of people here and in the states.

btw the Times is behind a paywall.

I imagine some folk on this board would know press reporters (I don't) I would at least like to know why this isn't mainstream news. I didn't get a PSA test as it was so iffy on results, a waste of time. If this had been around when I was looking I would have paid the £750, I'm not well off but what price life....

A couple of days ago some big bbc coverage on prostate cancer, but nothing about OBD's breakthrough.

I've not seen any in Telegraph or Guardian

If anyone has press contacts, please spread the news...

Maybe there has been some that I haven't seen...

This new bloke, Dr Sargeant's experience seems to be all in the medical side of things rather than hard headed business.

The results are dreadful and pathetic really, turnover about the same value as a 3 bed house in the south east.

All seems very Mickey Mouse when you read the financials from Co. inception to now, pretty much all minus signs.

And yet their website is very professional looking and well put together, their clients seem to like the Co. by giving them more work. But it's all peanuts.

Very dodgy in my opinion, I bought in last week...

I understand - sort of - what they do and how, not sure of their market - how big is their universe for good paying clients and how good is their PR (etc, etc)

I'll keep holding as I bought high when most were probably taking profits...

Not a big holding but Iwon't be pound cost averaging..

GLA

This Co. has got my notice and I've looked at their website but if anyone has some relevant info in layman's terms about them and could paste it here that would be great, things like their competition, why the SP history is so volatile - what caused the drops years ago, it would help me to invest - and others.

GLA Rob

JOHCM: Kooth en route to £100m annual recurring revenue

JOHCM’s Mark Costar tipped digital mental health and wellbeing company Kooth (KOO) to reach £100m annual recurring revenue and said its valuation is way off its potential.

Costar holds the Citywire Elite Company in his £227m JOHCM UK Growth fund and in a recent update noted Kooth’s ‘transformational contract win in California’ after it was awarded a £146m contract with the US state to provide digital mental health services to its six million 13-to-25-year olds.

‘As a reminder, this relative minnow on the UK stock market was selected in a competitive process involving 450 potential providers,’ Costar said.

‘In our opinion, the business is on a pathway to £100m annual recurring revenue in the long-run and a market valuation that still pales compared to its potential.’

Costar also noted that the company ‘raised growth funds at a premium to the prevailing market price’.

The shares retreated 2.6%, or 8.7p, to 320p on Monday.

I'm not an accountant and I always find BUR's accounts the most complicated out of any Co. There seems to be quite a few losses and not much coming in. I pretty well ignore any forward guidance as that's jam tomorrow not today. So far I think the market is unimpressed, but it's early and BUR is a limited market so things may change. Volume at 77 thousand pretty low. I was hoping for much more and ready to invest but I'm finding it all jam tomorrow as usual and so won't be.

Shame!!

I hope the results are good but I have no idea, Covid slowed down massively court judgements and so there's a backlog and I guess there won't be a huge increase to BUR coffers. I think Argentina will eventually pay up but that may be years away after elections and maybe a sensible Govt. It has a lot of resources but still is paying IMF interest (no capital) of 45 billion bailout, they got a recent IMF sum of 4 to 5 billion - but that was used to pay the interest on the 45 billion loan.
So for me it depends on what BUR says on it's other cases and it's overall cash position.